Figure 6From: Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancerFor small cell lung cancer, the MST and the 1- and 2-year survival rates of CRT group and RT group were 28 months, 72.7%, 58.2% and 15 months, 63.6%, 27.3% (χ2 = 0.884, p = 0.347), respectively.Back to article page